January 10, 2012
Asahi Kasei Pharma Corp.
Asahi Kasei Pharma’s licensing partner, Dong-A Pharmaceutical Co., Ltd. (Dong-A), has launched the sale of Flivas™ (naftopidil) in Korea as an agent for the treatment of benign prostatic hyperplasia (BPH) on January 2, 2012.
Asahi Kasei Pharma and Dong-A concluded a license agreement in April 2009, granting Dong-A exclusive rights for the development and sale of Flivas™ in Korea. Dong-A obtained approval from the Korea Food and Drug Administration (KFDA) as an agent for the treatment of BPH in April 2011.
BPH is a condition in which an enlarged prostate gland causes urinary symptoms such as discomfort, incontinence, incomplete voiding, and nocturia. Naftopidil is an α1-blocker that suppresses the constriction of smooth muscle in the prostate gland and in the urethra, alleviating the discomfort and other symptoms of BPH.
Flivas™ has played an important role in improving the quality of life for many patients in Japan. As the population ages, Flivas™ will be an increasingly vital therapy for a growing number of patients. The partnership with Dong-A, which has a wealth of experience in the field of urology, will facilitate the rapid establishment of a major presence of Flivas™ in the vital Korean market.
Product outline
| Product name: | Flivas™ |
|---|---|
| Generic name: | Naftopidil |
| Dosage and form: | 25 mg, 50 mg, and 75 mg tablet |
| Indication: | Dysuria associated with benign prostatic hyperplasia (BPH) |
| Price: | 375 won (25 mg), 600 won (50 mg), 733 won (75 mg) |
Corporate profile of Dong-A Pharmaceutical Co., Ltd.
| President: | Won-Bae Kim |
|---|---|
| Head office: | Seoul, Korea |
| Paid-in capital: | 55.7 billion won (as of Dec. 31, 2010) |
| Business line: | Production and sale of pharmaceuticals |
| Net sales: | 846.8 billion won (year ended Dec. 31, 2010) |
| Employees: | 2,282 |
Adobe Readeris required to view these PDF files.